Sight Sciences, Inc.
No SEC Form 4 filings for $SGHT in the last 30 days.
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
Sight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sght-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sight Sciences Reports Second Quarter 2026 Financial Results Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (
Sight Sciences (SGHT) said the FDA granted 510(k) clearance for its OMNI Ultra Surgical System, a handheld single-use device for minimally invasive glaucoma surgery. The system is indicated for canaloplasty followed by trabeculotomy to lower intraocular pressure in adults with primary open-angle glaucoma. The company plans a U.S. commercial launch in Q4 2026.
Over the past 7 days, alphai's AI scored 3 news stories mentioning SGHT (Sight Sciences, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent SGHT coverage spans financial news, market movers and earnings.
Guidance raise plus expense outlook reduction is a clear earnings-power upgrade that can re-rate the stock.
Guidance raise plus OpEx reduction signals improving operating leverage and cash discipline, supporting a bullish repricing versus prior expectations.
FDA clearance reduces regulatory overhang and supports commercialization planning, which can re-rate near-term risk for SGHT.
The filing discloses an insider accumulation signal, but it is a relatively small dollar amount and lacks a new operational catalyst.
The recent earnings report and FDA updates suggest positive momentum for Sight Sciences, with a somewhat bullish sentiment indicated by the ticker sentiment score.
alphai scores every news story that mentions SGHT with an AI model for sentiment and relevance, and aggregates insider trades from Sight Sciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Biotech gainers included Creative Medical (CELZ), up 71.95% after a new U.S. patent for exosome-based immunotherapy for Type 1 diabetes. Braveheart Bio (BRVE) jumped 65.56% on its Nasdaq debut. Iovance (IOVA) rose 43.09% after Q2 product revenue rose 66% to about $99M. Sight Sciences (SGHT) gained 27.75% after raising 2026 revenue guidance to $88M-$92M.
3 min readSight Sciences, Inc. (SGHT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sght-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Sight Sciences Reports Second Quarter 2026 Financial Results Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (
6 min readSight Sciences (SGHT) said the FDA granted 510(k) clearance for its OMNI Ultra Surgical System, a handheld single-use device for minimally invasive glaucoma surgery. The system is indicated for canaloplasty followed by trabeculotomy to lower intraocular pressure in adults with primary open-angle glaucoma. The company plans a U.S. commercial launch in Q4 2026.
3 min readEncrantz Staffan purchased 14,100 shares of Sight Sciences, Inc. (SGHT) at $4.88 on 2026-06-10.
1 min readSight Sciences, a medical technology company specializing in eye diseases, particularly glaucoma, is under investor focus following its recent earnings report and FDA updates. The company's revenue is driven by its glaucoma surgery platform, with growth influenced by procedure volumes, reimbursement trends, and surgeon adoption, while also investing in commercialization and R&D. While competition is intense, Sight Sciences positions itself through focused innovation and engagement with ophthalmic surgeons, making clinical data, competition, and healthcare policy key factors for investors to monitor.
4 min readSight Sciences (NASDAQ: SGHT) CTO David Badawi sold 8,168 shares of the company's stock on April 2nd at an average price of $3.48, totaling approximately $28,424. This sale reduced his position by 0.41% to 1,990,290 shares. The company's stock has a 12-month range of $2.03-$9.24 and a "Hold" consensus rating from analysts with an $8.31 average target price.
4 min readSight Sciences (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
3 min readMENLO PARK, Calif., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc. ( NASDAQ:SGHT ) ( Sight Sciences, or the Company ) , an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, announced ...
3 min readThe headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
3 min readSight Sciences (SGHT) delivered earnings and revenue surprises of +38.46% and +15.98%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
